CDRT15P14

Across TCGA pan-cancer cohorts, CDRT15P14 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated CDRT15P14 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CDRT15P14 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDRT15P14 expression acts as an unfavorable survival marker, although some lineages such as ACC and LUAD show a favorable association.

STAD, BRCA, and KIRP are the cancer types where CDRT15P14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	IV	0.112	0.683	<.001	100	view →
BRCA	OS	Quartile	IV	0.358	0.844	.002	32	view →
KIRP	DFS	Tertile	All	0.853	0.947	.005	30	view →
BLCA	OS	Tertile	IV	0.279	0.539	.005	25	view →
DLBC	OS	Quartile	IV	0.235	0.897	.016	21	view →
KIRC	DFS	Tertile	IV	0.202	0.502	.024	18	view →
ACC	DFS	Median	IV	0.620	0.128	<.001	18	view →
LUAD	DFS	Median	III,IV	0.570	0.257	.014	14	view →
CESC	DFS	Median	II,III,IV	0.814	0.612	.009	8	view →
PAAD	OS	Median	All	0.690	0.560	.027	6	view →
MESO	OS	Tertile	IV	0.959	0.301	.021	6	view →
THCA	OS	Quartile	All	0.957	0.987	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

CDRT15P14–STAD (DFS)

Open the STAD breakdown →